Participants: Warren Sherman (Chair), Columbia University Medical Center; Albert Assad, Celgene; Elmar Burchardt, Pfizer; George Cole Jr, Miltenyi Biotec Inc.; Robert Deans, Athersys Inc.; Ed Field, Aldagen; Jim Hinson, Aldagen Inc.; Anthony Kihm, Advanced Technologies and Regenerative Medicine; Keith March, Indiana University; Chaya Mazouz, Pluristem Therapeutics; Mike Murphy, Indiana University; Thomas O'Donnell, Tufts-New England Medical Center; Amit Patel, University Of Utah; Marc Penn, Cleveland Clinic; David Peritt, Hospira Inc.; James Powell, Pfizer Inc.; Amish Raval, University of Wisconsin; Weiyong Sun, Daiichi Sankyo; Anthony Ting, Athersys Inc.; Sharon Watling, Aastrom Biosciences; Andreas Zeiher, University of Frankfurt.
Report prepared by: Warren Sherman (Chair), Columbia University Medical Center; Chaya Mazouz, Pluristem Therapeutics; Robert Deans, Athersys Inc.; Amit Patel, University Of Utah.
Declaration of interest: Warren Sherman Chairs the DSMB of several CHF clinical trials for Aastrom and Harvest, and is a co-PI for a clinical trail sponsored by Athersys. Chaya Mazouz is employed by Pluristem. Robert Deans is employed by Athersys. Amit Patel is the principal investigator of clinical trials sponsored by Aastrom and Harvest. The authors alone are responsible for the content and writing of this paper.